Market Overview

Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen


In a report published Friday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ: PCYC), and raised the price target from $233.00 to $261.00.

In the report, Credit Suisse noted, "We are increasing our target price to $261, the agreed purchase price from ABBV, from $233. We believe the probability of the deal closing is very high. PCYC's remarkable rise highlights the power of a truly novel, first-in-class drug to both impact patients and create huge value for shareholders. We view the ABBV deal as rational, creating the leading franchise in CLL and NHL, with potential upside in solid tumors, multiple myeloma, and autoimmune disease. Given all that has been said about the drug, the deal price, and the strategic rationale, we thought it was worthwhile reflecting on some of the champions of this program at PCYC (see page 2 for our thoughts on the deal)."

Pharmacyclics closed on Thursday at $254.22.

Latest Ratings for PCYC

Mar 2015Leerink SwannDowngradesOutperformMarket Perform
Mar 2015NomuraDowngradesBuyNeutral
Mar 2015Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings


Related Articles (PCYC)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Jason KantorAnalyst Color Price Target Analyst Ratings

Latest Ratings

VNRXAegis CapitalMaintains10.0
TRVMorgan StanleyMaintains155.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at